Tribunnews Reporter, Fitri Wulandari
TRIBUNNEWS.COM, COPENHAGEN – Bavarian Nordic experienced a bit of a shock since the spread of the monkeypox virus (Monkeypox), with the purchase of shares of the vaccine manufacturer due to the increasing cases of Monkeypox.
Shares of the Danish biotechnology company have gained 69 percent since hitting their lowest point in early May.
At the same time, cases of the Monkeypox virus have jumped from just a handful in Europe at the start of last month, to more than 1,200 cases.
In addition, this case was also found in America, the Middle East and Australia in early June.
Quoted from the Bloomberg page, Friday (17/6/2022), the producer of the only Monkeypox vaccine approved for use by the United States (US) Food and Drug Administration (FDA) will get around 39 percent of its total revenue in 2021 from the Jynneos vaccine. .
The vaccine is the approved vaccine for smallpox and Monkeypox in the US and Canada as well as Europe.
Chief Financial Officer Bavarian NordicHenrik Juuel said earlier this month that the interest from various governments in purchasing the vaccine was ‘remarkable’.
Investors also noticed the company’s shares, which had previously slumped along with other biotechs in a rout in share growth this year, have bounced back, posting several days of big gains over the past month.
Also read: WHO Interim Guidance on Vaccines and Immunizations for Monkeypox
According to the company’s communications partner, Thomas Duschek, the impact of its share purchase, Bavarian Nordic gained as many as 5,000 new investors over the past month, bringing the total to 118,000.
–
